SS-31 vs MOTS-c: where each works and what the human data show

Reviewed 18 sourcesPublished by PepVault

SS-31 vs MOTS-c side by side: where each acts in the mitochondrion, the human evidence for each in one table, and what is known about taking them together.

A woman in a coral tank top standing on a paddleboard in a green bay at sunrise
Last reviewed
Sources
18
Questions
8
Compounds
2

The short answer

SS-31 and MOTS-c both target mitochondria, from opposite sides. SS-31 (elamipretide) is a lab-made, four-amino-acid drug that sits on cardiolipin in the inner membrane; the FDA approved it in 2025 for Barth syndrome, though its larger trials missed. MOTS-c is a 16-amino-acid signal the mitochondria make themselves, strong in mice but never given to people in a published trial.

Every number checked at its primary source · · 18 sources · How we research

Evidence: Uneven: SS-31 has randomized human trials, mostly negative, and an FDA accelerated approval in Barth syndrome built on 12 patients; MOTS-c's effects as a treatment come from mouse and cell studies, with human data limited to the body's own levels, genetics and one analog trial.

A woman in a coral tank top standing on a paddleboard in a green bay at sunrise

What is the difference between SS-31 and MOTS-c?

Mitochondria are the structures inside cells that turn food and oxygen into ATP, the cell's energy currency. Both are called mitochondrial peptides, a label that hides how different they are. SS-31 is a drug that chemists designed: four amino acids, one of them a modified tyrosine and one a mirror-image arginine, small enough to slip into the cell and settle on the inner mitochondrial membrane12. MOTS-c is something your body already makes. Its recipe is written in the mitochondria's own small genome, inside the gene for a ribosomal RNA, and it is 16 amino acids long417.

Put simply, SS-31 is a repair crew on the factory floor, and MOTS-c is a message the factory sends out to the rest of the cell.

At a glanceSS-31 (elamipretide)MOTS-c
Where it comes fromDesigned in a lab; not made by the bodyMade by the body, coded in mitochondrial DNA
Size4 amino acids, about 640 daltons (749 as the label's salt)216 amino acids, about 2,175 daltons17
Where it actsOn the inner mitochondrial membrane2Outside the mitochondria: the cell's fluid and its nucleus45
What it binds or switches onCardiolipin, a membrane fat1AMPK, the cell's fuel gauge4
Status, November 2026FDA-approved for Barth syndrome (accelerated)3Not approved; the FDA lists compounding risks, and its compounding nomination was withdrawn12
Published human trials of the moleculeSeveral, including a 218-person phase 37None
A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

In PepVault both fit one protocol: SS-31 every day and MOTS-c on the days you pick, such as Monday, Wednesday and Friday. Each can have its own reminder time, and Today shows only what is due.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where does each act in the mitochondrion?

A mitochondrion has two membranes. The inner one is folded into ridges called cristae, and that is where the chain of enzymes that makes ATP sits. A fat called cardiolipin is found only in that inner membrane: it holds the folds in shape, keeps the enzymes packed together so they work as a chain, and decides whether a protein called cytochrome c carries electrons, its normal job, or turns into an enzyme that damages fats1. SS-31 binds cardiolipin through electric charge and water-repelling contacts, keeps cytochrome c on its normal job and protects the cristae1. The FDA label puts it in one line: a cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial shape and function2.

MOTS-c does its work after it leaves. In the 2015 paper that named it, its main target was skeletal muscle: it slowed the folate cycle and the purine building tied to it, and that switched on AMPK, the enzyme that senses low energy and tells the cell to take up and burn more glucose and fat4. In 2018 the same lab showed that under metabolic stress, such as glucose running short, MOTS-c moves into the nucleus and changes which of the nucleus's genes are read, including antioxidant-defence genes run by a switch called NRF25.

Both mechanisms come from cell and animal studies (pepvault.app/glossary/in-vitro and /glossary/in-vivo). Results in cells and mice often don't carry over to people, which is why the next table matters more.

What is the human evidence for SS-31 and MOTS-c?

SS-31 has been given to hundreds of people in controlled trials. MOTS-c has been measured in people and studied through their genes, but every published study that gave it as a treatment used mice or cells. The one human drug trial in its family tested an analog, a modified molecule, CB4211.

StudyPeptideWhoWhat it found
TAZPOWER, on the label2SS-3112 people with Barth syndrome, 40 mg a dayMissed both main goals over 12 randomized weeks; knee strength rose in the open-label years after, the basis of the 2025 approval
MMPOWER-3, 20237SS-31218 adults with mitochondrial myopathy, 40 mg a day for 24 weeksNo benefit: walk-test difference of -3.2 m against placebo (p = 0.69)
Roshanravan, 20218SS-3139 adults aged 60 to 85, one 2-hour infusionMuscle energy capacity rose right after the dose, gone by day 7; no change in fatigue resistance
Reynolds, 20216MOTS-c (the body's own)10 sedentary young men, one cycling sessionMuscle MOTS-c up 11.9-fold; blood up 1.6-fold, back to baseline 4 hours later
Zempo, 20219MOTS-c (a gene variant)27,527 people in three cohorts, two in Japan, one in the USMen, not women, carrying the K14Q variant, which swaps one amino acid, had more type 2 diabetes
CB4211 phase 1b1011A MOTS-c analog20 people with fatty liver, 25 mg or placebo daily for 4 weeksALT, a liver-damage marker, down 21% against up 4%; liver fat fell 5.03 points against 4.88 on placebo

SS-31 is the only one of the two with randomized evidence in people, and most of it is negative or short: the approval rests on 12 patients and an open-label extension, meaning everyone knew they were on the drug2. MOTS-c's human record is a set of strong clues, since exercise raises it and a variant that weakens it tracks with diabetes, but none shows what an injection does. The FDA's compounding page, current as of April 22, 2026, says the agency has not identified any human exposure data on drug products containing MOTS-c given by any route12.

Which SS-31 trials are still to report?

As of November 2026, ClinicalTrials.gov lists the next readouts for SS-31, all from or with its developer, Stealth BioTherapeutics:

  • ReNEW: 313 people with dry age-related macular degeneration, enrolment closed, main results due around August 202713.
  • 4TAZPower: the confirmatory Barth syndrome trial that continued approval may depend on, 48 people, due around September 202914.
  • SHAPE: a University of Washington pilot in 30 healthy adults aged 65 to 80, a daily injection for 4 weeks, open-label and mainly a safety test; its listed end date, April 2026, has passed with no update15.
  • NuPower: 102 people with mitochondrial disease from nuclear DNA mutations, completed in 2024, with no results posted18.

MOTS-c has no published trial to wait on, and CB4211's topline numbers, released in 2021 and restated in a 2022 annual filing, have had no paper since10.

How are SS-31 and MOTS-c dosed, and how long do they last?

The SS-31 label dose for Barth syndrome is 40 mg injected under the skin once a day, the dose most of its long trials used27. It peaks in the blood 30 to 60 minutes after the injection, about 92% of it reaches the bloodstream, and by 48 hours about 100% of the dose has left in the urine2. The label gives no half-life figure, and the older-adult study's effect was gone a week after one dose8. MOTS-c has no published human pharmacokinetics at all. The half-lives some comparison pages print, 30 minutes for MOTS-c and 2 hours for SS-31, cite no source.

DosingSS-31MOTS-c
Label or trial schedule40 mg once a day, under the skin2None in people; mouse studies dosed by body weight46
Community scheduleUsually 2 to 4 mg a dayUsually 5 to 10 mg, 2 or 3 times a week
Peak in blood30 to 60 minutes2Not measured in people

The community amounts come from protocols, not studies. For SS-31 they sit far below the label's 40 mg, though the label notes that blood levels rise in step with the dose across 2 to 80 mg2. Both ranges, with that caveat, are at pepvault.app/lab/dosage/ss-31 and pepvault.app/lab/dosage/mots-c.

These are the amounts the label, the trials and community protocols describe, not a protocol to copy.

Can you take SS-31 and MOTS-c together?

People do: it is a common longevity pairing, and the two make up the Longevity Core stack with epitalon (pepvault.app/stacks/mots-c-epitalon-ss-31). The rationale follows the mechanisms. SS-31 protects the membrane where energy is made; MOTS-c changes how the cell spends fuel. Because they act on different targets, neither is expected to block the other.

No study has tested that. A PubMed search for both names together (November 20, 2026) returns one record, a 2026 review of peptides in sports medicine that covers each one separately16. The advice some sellers give, to run SS-31 for weeks first and add MOTS-c later, is opinion. Because MOTS-c works on glucose handling in animals4, anyone on insulin or other diabetes medicine has good reason to talk glucose with their doctor first.

In PepVault both fit one protocol: SS-31 every day and MOTS-c on the days you pick, such as Monday, Wednesday and Friday. Each can have its own reminder time, and Today shows only what is due. Set reminders in PepVault

Commonly reported: on SS-31, steadier energy and less of a crash after exercise, building over weeks; on MOTS-c, a tired first week or two, then easier workouts by weeks two to four.

What side effects do SS-31 and MOTS-c cause?

For SS-31 the label has real numbers. In the Barth trial, all 12 patients had redness at the injection site on elamipretide, against 3 of 12 on placebo, and 75% had pain there2. Eosinophils, a type of white blood cell, often rose in courses of a month or more, peaked around day 90 and settled after 6 to 12 months, with no symptoms attached2. In MMPOWER-3 most side effects were mild to moderate7.

For MOTS-c there is no human safety data. The nearest is the analog: CB4211's volunteers had mild, mostly painless bumps under the skin where they injected, which stopped lasting after a change of formulation10. The FDA's concern with compounded MOTS-c is immunogenicity, the chance the immune system reacts against the peptide (pepvault.app/glossary/immunogenicity)12.

Two injected peptides means more sites to rotate. Each shot you log in PepVault records where it went, so the last few sites are in front of you before the next one. Log it in PepVault

When to get help If a rash, a cough or other signs of an allergic reaction follow a dose, the SS-31 label's advice is to stop and get medical help right away2.

Where to read more

  • Each one in depth: the guides SS-31 (elamipretide), what the trials show, and MOTS-c, the mouse and human studies.
  • The library pages, pepvault.app/peptides/ss-31 and pepvault.app/peptides/mots-c, with their legal status pages, and the short comparison at pepvault.app/peptides/compare/mots-c-vs-ss-31.
  • The study pages, such as pepvault.app/research/ss-31-mmpower-3-2023, pepvault.app/research/ss-31-roshanravan-2021, pepvault.app/research/mots-c-lee-2015 and pepvault.app/research/mots-c-reynolds-2021.
  • Open-label, primary endpoint and accelerated approval are explained at pepvault.app/glossary/open-label, /glossary/primary-endpoint and /glossary/accelerated-approval.
  • Next guide: NAD+ vs NMN vs NR, what each is and what the human trials measured.

Track it in the app

Sources

  1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. PubMed 24117165
  2. FORZINITY (elamipretide) injection, prescribing information. Stealth BioTherapeutics. DailyMed, version 11, November 6, 2026. dailymed.nlm.nih.gov
  3. U.S. Food and Drug Administration. Drugs@FDA: NDA 215244, Forzinity (elamipretide), original approval September 19, 2025 (Type 1, new molecular entity). accessdata.fda.gov
  4. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PubMed 25738459
  5. Kim KH et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018. PubMed 29983246
  6. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PubMed 33473109
  7. Karaa A et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023. PubMed 37268435
  8. Roshanravan B et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. PubMed 34264994
  9. Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021. PubMed 33468709
  10. CohBar, Inc. Annual report on Form 10-K for 2021, filed with the U.S. Securities and Exchange Commission, March 29, 2022. sec.gov
  11. ClinicalTrials.gov NCT03998514. A phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease. Sponsor: CohBar, Inc. clinicaltrials.gov
  12. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
  13. ClinicalTrials.gov NCT06373731. ReNEW: phase 3 of subcutaneous elamipretide in dry age-related macular degeneration. Sponsor: Stealth BioTherapeutics Inc. Record updated September 17, 2026. clinicaltrials.gov
  14. ClinicalTrials.gov NCT07531251. 4TAZPower: confirmatory trial of elamipretide in Barth syndrome. Sponsor: Stealth BioTherapeutics Inc. clinicaltrials.gov
  15. ClinicalTrials.gov NCT07275424. SHAPE: open-label phase 2a pilot of daily subcutaneous elamipretide in older adults. Sponsor: University of Washington (D. Marcinek), with Stealth BioTherapeutics. clinicaltrials.gov
  16. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026. PubMed 41966639
  17. UniProt A0A0C5B5G6. Mitochondrial-derived peptide MOTS-c (human, gene MT-RNR1): sequence and mass. rest.uniprot.org
  18. ClinicalTrials.gov NCT05162768. NuPower: elamipretide in primary mitochondrial disease from nuclear DNA mutations. Sponsor: Stealth BioTherapeutics Inc. clinicaltrials.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo